Current Development of siRNA Bioconjugates: From Research to the Clinic
Small interfering RNAs (siRNAs) acting via RNA interference mechanisms are able to recognize a homologous mRNA sequence in the cell and induce its degradation. The main problems in the development of siRNA-based drugs for therapeutic use are the low efficiency of siRNA delivery to target cells and t...
Saved in:
Main Authors: | Ivan V. Chernikov (Author), Valentin V. Vlassov (Author), Elena L. Chernolovskaya (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene
by: Ivan V. Chernikov, et al.
Published: (2017) -
Folate-Equipped Cationic Liposomes Deliver Anti-MDR1-siRNA to the Tumor and Increase the Efficiency of Chemotherapy
by: Daniil V. Gladkikh, et al.
Published: (2021) -
Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
by: Alexey Berezhnoy, et al.
Published: (2012) -
Antibody-siRNA conjugates (ARC): Emerging siRNA drug formulation
by: Weiran Cao, et al.
Published: (2022) -
Nanoparticles and siRNA: A new era in therapeutics?
by: María Dolores Pérez-Carrión, et al.
Published: (2024)